{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=bevacizumab&page=12", "query": { "intervention": "bevacizumab", "page": 12 }, "page_size": 10 }, "pagination": { "page": 12, "page_size": 10, "total_count": 1372, "total_pages": 138, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=bevacizumab&page=13&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=bevacizumab&page=11&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-26T11:22:26.260Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00095225", "title": "A Study to Evaluate Bevacizumab and Chemotherapy or Tarceva in Treating Recurrent or Refractory NSCLC (Non-Small Cell Lung Cancer)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small-Cell Lung Carcinoma", "Neoplasm Recurrence, Local" ], "interventions": [ { "name": "Avastin (bevacizumab)", "type": "DRUG" }, { "name": "Tarceva (erlotinib HCl)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 122, "start_date": "2004-07", "completion_date": "2006-11", "has_results": false, "last_update_posted_date": "2008-01-29", "last_synced_at": "2026-10-26T11:22:26.260Z", "location_count": 48, "location_summary": "Bakersfield, California • Concord, California • Fullerton, California + 40 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Concord", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Greenbrae", "state": "California" }, { "city": "Laverne", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00095225" }, { "nct_id": "NCT04068610", "title": "COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Microsatellite-stable Colorectal Cancer" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Oleclumab", "type": "DRUG" }, { "name": "FOLFOX", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MedImmune LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "101 Years", "sex": "ALL", "summary": "18 Years to 101 Years" }, "enrollment_count": 61, "start_date": "2019-09-13", "completion_date": "2026-11-24", "has_results": true, "last_update_posted_date": "2026-08-11", "last_synced_at": "2026-10-26T11:22:26.260Z", "location_count": 11, "location_summary": "Los Angeles, California • Sacramento, California • Ann Arbor, Michigan + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04068610" }, { "nct_id": "NCT01243359", "title": "Sunitinib Malate and Bevacizumab in Treating Patients With Kidney Cancer or Advanced Solid Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Clear Cell Renal Cell Carcinoma", "Recurrent Renal Cell Cancer", "Stage I Renal Cell Cancer", "Stage II Renal Cell Cancer", "Stage III Renal Cell Cancer", "Stage IV Renal Cell Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "sunitinib malate", "type": "DRUG" }, { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "fluorine F 18 fluorothymidine", "type": "OTHER" }, { "name": "positron emission tomography", "type": "PROCEDURE" }, { "name": "computed tomography", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2010-10", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-04-02", "last_synced_at": "2026-10-26T11:22:26.260Z", "location_count": 2, "location_summary": "Baltimore, Maryland • Madison, Wisconsin", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT01243359" }, { "nct_id": "NCT07278336", "title": "A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ovarian Cancer" ], "interventions": [ { "name": "ABBV-901", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 285, "start_date": "2025-11-27", "completion_date": "2029-01", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-26T11:22:26.260Z", "location_count": 8, "location_summary": "Duarte, California • Irvine, California • Denver, Colorado + 5 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT07278336" }, { "nct_id": "NCT06011109", "title": "Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Glioma", "Glioblastoma Multiforme" ], "interventions": [ { "name": "APG-157", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aveta Biomics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 30, "start_date": "2023-12-13", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-10-26T11:22:26.260Z", "location_count": 2, "location_summary": "Rochester, Minnesota • Omaha, Nebraska", "locations": [ { "city": "Rochester", "state": "Minnesota" }, { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT06011109" }, { "nct_id": "NCT00941499", "title": "Hepatic Arterial Infusion Oxaliplatin + 5FU, Leucovorin, and Bevacizumab +/- Cetuximab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancers" ], "interventions": [ { "name": "HAI Oxaliplatin", "type": "DRUG" }, { "name": "5-FU", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 140, "start_date": "2009-07", "completion_date": "2014-05", "has_results": false, "last_update_posted_date": "2015-11-18", "last_synced_at": "2026-10-26T11:22:26.260Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00941499" }, { "nct_id": "NCT05482893", "title": "Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Gastric or Gastroesophageal Junction Adenocarcinoma", "Pancreatic Ductal Adenocarcinoma", "Biliary Tract Cancer (BTC)", "Colorectal Cancer" ], "interventions": [ { "name": "Spevatamig (PT886)", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Abraxane", "type": "DRUG" }, { "name": "KEYTRUDA® (pembrolizumab)", "type": "DRUG" }, { "name": "FOLFOX", "type": "DRUG" }, { "name": "CAPOX", "type": "DRUG" }, { "name": "FOLFIRINOX", "type": "DRUG" }, { "name": "TAS 102", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Gemcitabine Combined With Cisplatin", "type": "DRUG" }, { "name": "NALIRIFOX", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Phanes Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 350, "start_date": "2023-03-15", "completion_date": "2028-04", "has_results": false, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-10-26T11:22:26.260Z", "location_count": 11, "location_summary": "Duarte, California • Los Angeles, California • Denver, Colorado + 8 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT05482893" }, { "nct_id": "NCT01231633", "title": "Comparison of Initial Ozurdex (Dexamethasone Implant) to Avastin (Bevacizumab) for Treatment of Macular Edema Caused by Central Retinal Vein Occlusion (CRVO)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Macular Edema", "Central Retinal Vein Occlusion" ], "interventions": [ { "name": "Ozurdex", "type": "DRUG" }, { "name": "Avastin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Long Island Vitreoretinal Consultants", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2010-09", "completion_date": "2014-09", "has_results": true, "last_update_posted_date": "2018-04-03", "last_synced_at": "2026-10-26T11:22:26.260Z", "location_count": 4, "location_summary": "Toms River, New Jersey • Great Neck, New York • Hauppauge, New York + 1 more", "locations": [ { "city": "Toms River", "state": "New Jersey" }, { "city": "Great Neck", "state": "New York" }, { "city": "Hauppauge", "state": "New York" }, { "city": "Riverhead", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01231633" }, { "nct_id": "NCT03423823", "title": "Ziv-aflibercept Efficacy in Better Regulating AMD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Wet Macular Degeneration", "Wet Age-related Macular Degeneration" ], "interventions": [ { "name": "Ziv-Aflibercept 25 MG/ML [Zaltrap]", "type": "DRUG" }, { "name": "Ranibizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kapil Kapoor", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "50 Years to 99 Years" }, "enrollment_count": 62, "start_date": "2017-07-07", "completion_date": "2020-06-26", "has_results": false, "last_update_posted_date": "2020-10-06", "last_synced_at": "2026-10-26T11:22:26.260Z", "location_count": 1, "location_summary": "Virginia Beach, Virginia", "locations": [ { "city": "Virginia Beach", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03423823" }, { "nct_id": "NCT05739981", "title": "Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Ovarian Cancer", "Fallopian Tube Cancer", "Primary Peritoneal Cancer" ], "interventions": [ { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "IMNN-001", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Imunon", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 30, "start_date": "2023-02-10", "completion_date": "2028-08-30", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-10-26T11:22:26.260Z", "location_count": 4, "location_summary": "Baltimore, Maryland • New York, New York • Oklahoma City, Oklahoma + 1 more", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "New York", "state": "New York" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05739981" } ] }